Tricyclic dihydroquinazolinones as novel 5-HT2C selective and orally efficacious anti-obesity agents

Bioorganic and Medicinal Chemistry Letters

Volumn 20, Issue 3, 2010, Pages 1128-1133

  Ahmad, Saleem ^a   Ngu, Khehyong ^a   Miller, Keith J ^a   Wu, Ginger ^a   Hung, Chen pin ^a   Malmstrom, Sarah ^a   Zhang, Ge ^a   O'Tanyi, Eva ^a   Keim, William J ^a   Cullen, Mary Jane ^a   Rohrbach, Kenneth W ^a   Thomas, Michael ^a   Ung, Thao ^a   Qu, Qinling ^a   Gan, Jinping ^a   Narayanan, Rangaraj ^a   Pelleymounter, Mary Ann ^a   Robl, Jeffrey A ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

Obesity; Serotonin

Indexed keywords

6,6,6 DIHYDROQUINAZOLINONE; 6,6,7 DIHYDROQUINAZOLINONE; ANTIOBESITY AGENT; DIHYDROQUINAZOLINONE; QUINAZOLINONE DERIVATIVE; SEROTONIN 2B RECEPTOR; UNCLASSIFIED DRUG; PROTEIN BINDING; SEROTONIN 2 AGONIST; SEROTONIN 2C RECEPTOR; SEROTONIN AGONIST;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG EFFICACY; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG SYNTHESIS; IN VIVO STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; OBESITY; RAT; TIME TO MAXIMUM PLASMA CONCENTRATION; WEIGHT REDUCTION; ANIMAL; CHEMISTRY; COMPARATIVE STUDY; DRUG EFFECTS; EATING; HUMAN; METABOLISM; ORAL DRUG ADMINISTRATION; PHYSIOLOGY; SPRAGUE DAWLEY RAT;

ANIMALIA; RATTUS;

ADMINISTRATION, ORAL; ANIMALS; ANTI-OBESITY AGENTS; EATING; HUMANS; MALE; OBESITY; PROTEIN BINDING; QUINAZOLINONES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, SEROTONIN, 5-HT2C; SEROTONIN 5-HT2 RECEPTOR AGONISTS; SEROTONIN RECEPTOR AGONISTS;

EID: 74049112977     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2009.12.014     Document Type: Article

References (27)

1. Monck N.J.T., and Kennett G.A. Prog. Med. Chem. 46 (2008) 281
2. Miller K.J. Mol. Interventions 5 (2005) 282
3. Vickers S.P., Benwell K.R., Porter R.H., Bickerdike M.J., Kennett G.A., and Dourish C.T. Br. J. Pharmacol. 130 (2000) 1305
4. Dunlop J., Marquis K.L., Lim H.K., Leung L., Kao J., Cheesman C., and Rosenzweig-Lipson S. CNS Drug Rev. 12 (2006) 167
5. Zhou L., Sutton G.M., Rochford J.J., Semple R.K., Lam D.D., Oksanen L.J., Thornton-Jones Z.D., Clifton P.G., Yueh C.-Y., Evans M.L., McCrimmon R.J., Elmquist J.K., Butler A.A., and Heisler L.K. Cell Metabolism 6 (2007) 398
6. Wacker D.A., and Miller K.J. Curr. Opin. Drug Discov. Devel. 11 (2008) 438
7. Allerton C.M.N., Andrews M.D., Blagg J., Ellis D., Evrard E., Green M.P., Liu K.K.-C., McMurray G., Ralph M., Sanderson V., Ward R., and Watson L. Bioorg. Med. Chem. Lett. 19 (2009) 5791
8. Andrews M.D., Green M.P., Allerton C.M.N., Batchelor D.V., Blagg J., Brown A.D., Gordon D.W., McMurray G., Millns D.J., Nichols C.L., and Watson L. Bioorg. Med. Chem. Lett. 19 (2009) 5343
9. Fish P.V., Brown A.D., Evrard E., and Roberts L.R. Bioorg. Med. Chem. Lett. 19 (2009) 1871
10. Walsh A.E.S., Smith K.A., Oldman A.D., Williams C., Goodall E.M., and Cowen P.J. Psychopharmacology 116 (1994) 120
11. Kennett G.A., Wood M.D., Bright F., Trail B., Riley G., Holland V., Avenell K.Y., Stean T., Upton N., Bromidge S., Forbes I.T., Brown A.M., Middlemiss D.N., and Blackburn T.P. Neuropharmacology 36 (1997) 609
12. Tecott L.H., Sun L.M., Akana S.F., Strack A.M., Lowenstein D.H., Dallman M.F., and Julius D. Nature 374 (1995) 542
13. Vickers S.P., Clifton P.G., Dourish C.T., and Tecott L.H. Psychopharmacology 143 (1999) 309
14. Sargent P.A., Sharpley A.L., Williams C., Goodall E.M., and Cowen P.J. Psychopharmacology 133 (1997) 309
15. Fitzgerald L.W., Burn T.C., Brown B.S., Patterson J.P., Corjay M.H., Valentine P.A., Sun J.-H., Link J.R., Abbaszade I., Hollis J.M., Largent B.L., Hartig P.R., Hollis G.F., Meunier P.C., Robichaud A.J., and Robertson D.W. Mol. Pharmacol. 57 (2000) 75
16. Rothman R.B., Baumann M.H., Savage J.E., Rauser L., McBride A., Hufeisen S.J., and Roth B.L. Circulation 102 (2000) 2836
17. Roth B.L., Willins D.L., Kristiansen K., and Kroeze W.K. Pharmacol. Ther. 79 (1998) 231
18. Thomsen W.J., Grottick A.J., Menzaghi F., Reyes-Saldana H., Espitia S., Yuskin D., Whelan K., Martin M., Morgan M., Chen W., Al-Shamma H., Smith B., Chalmers D., and Behan D. J. Pharmacol. Exp. Ther. 325 (2008) 577
19. Smith S.R., Prosser W.A., Donahue D.J., Morgan M.E., Anderson C.M., and Shanahan W.R. Obesity 17 (2009) 494
20. Smith B.M., Smith J.M., Tsai J.H., Schultz J.A., Gilson C.A., Estrada S.A., Chen R.R., Park D.M., Prieto E.B., Gallardo C.S., Sengupta D., Dosa P.I., Covel J.A., Ren A., Webb R.R., Beeley N.R.A., Martin M., Morgan M., Espitia S., Saldana H.R., Bjenning C., Whelan K.T., Grottick A.J., Menzaghi F., and Thomsen W.J. J. Med. Chem. 51 (2008) 305
21. The condensation could also be carried out in refluxing dioxane in the presence of catalytic p-toluenesulfonic acid.
22. 2C binding activities between the two enantiomers.
23. 384 (Molecular Devices, Sunnyvale, CA). See Ref. 15 for complete description of all in vitro and in vivo assays.
24. Wacker D.A., Varnes J.G., Malmstrom S.E., Cao X., Hung C.-P., Ung T., Wu G., Zhang G., Zuvich E., Thomas M.A., Keim W.J., Cullen M.J., Rohrbach K.W., Qu Q., Narayanan R., Rossi K., Janovitz E., Lehman-McKeeman L., Malley M.F., Devenny J., Pelleymounter M.A., Miller K.J., and Robl J.A. J. Med. Chem. 50 (2007) 1365
25. Bromidge S.M., Dabbs S., Davies D.T., Davies S., Duckworth D.M., Forbes I.T., Gaster L.M., Ham P., Jones G.E., King F.D., Mulholland K.R., Saunders D.V., Wyman P.A., Blaney F.E., Clarke S.E., Blackburn T.P., Holland V., Kennett G.A., Lightowler S., Middlemiss D.N., Trail B., Riley G.J., and Wood M.D. J. Med. Chem. 43 (2000) 1123
26. 2C antagonist SB243213. SB243213 alone produced a significant 26.7% increase in food consumption at the 10 mpk dose.
27. i = 8.6 nM) displayed by (+)-2a supports potent antagonism at the receptor.